Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Prospective Study to Acess Long-term Benefit in HBeAg Positive Chronic Hepatitis B Patients Who Previously Received Standard Peginterferon Alfa Therapy

NCT03181113 is registered in ClinicalTrials.gov with Xiamen Amoytop Biotech Co., Ltd. as lead sponsor.

NCT NCT03181113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03181113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Prospective Study to Acess Long-term Benefit in HBeAg Positive Chronic Hepatitis B Patients Who Previously Received Standard Peginterferon Alfa Therapy
Lead sponsor
Xiamen Amoytop Biotech Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
May 18, 2016
Completion date
September 21, 2020
Enrollment
473 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b